Replies to Post #1840 onEnanta Pharmaceuticals Inc (ENTA) | InvestorsHub

S&P 500

US TECH 100

Dow Jones

Brent Oil

Bitcoin

Replies to post #1840 on Enanta Pharmaceuticals Inc (ENTA)

Replies to #1840 on Enanta Pharmaceuticals Inc (ENTA)

02/06/20 4:34 PM

#1842 RE: DewDiligence #1840

ENTA new corporate slide set:

https://s22.q4cdn.com/306858242/files/doc_presentations/2020/01/Final-Jan.-13-2020-JP-Morgan-Corporate-Presentation.pdf

02/10/20 5:47 PM

#1848 RE: DewDiligence #1840

ENTA FY1Q20 CC transcript:

https://finance.yahoo.com/news/edited-transcript-enta-earnings-conference-185401314.html

05/06/20 4:14 PM

#1875 RE: DewDiligence #1840

ENTA FY2Q20 results—royalty revenue=$27.6M—GAAP EPS=($0.30):

https://www.enanta.com/investors/news-releases/press-release/2020/Enanta-Pharmaceuticals-Reports-Financial-Results-for-its-Fiscal-Second-Quarter-Ended-March-31-2020-with-Webcast-and-Conference-Call-Today-at-430-pm-ET/default.aspx

I expected FY2Q20 financial results to be bad for the reasons in #msg-155360453.

The 3/31/20 cash balance was $435M.